Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Sell
48
IMRX Quote, Financials, Valuation and Earnings
Last price:
$2.27
Seasonality move
:
-14.17%
Day range:
$1.96 - $2.24
52-week range:
$1.00 - $7.92
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
205.01x
P/B ratio:
1.18x
Volume:
597.8K
Avg. volume:
720K
1-year change:
-68.57%
Market cap:
$68.3M
Revenue:
--
EPS (TTM):
-$1.97
Analysts' Opinion
-
Consensus RatingImmuneering has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Immuneering has an estimated upside of 464.39% from its current price of $2.20.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $2.20.
Fair Value
-
According to the consensus of 5 analysts, Immuneering has 464.39% upside to fair value with a price target of -- per share.
IMRX vs. S&P 500
-
Over the past 5 trading days, Immuneering has overperformed the S&P 500 by 25% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Immuneering does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Immuneering revenues have been falling on a year-over-year basis for 6 quarters in a row. In the most recent quarter Immuneering reported revenues of --.
Earnings Growth
-
Immuneering has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Immuneering reported earnings per share of -$0.49.
Enterprise value:
17.7M
EV / Invested capital:
--
Price / LTM sales:
205.01x
EV / EBIT:
--
EV / Revenue:
55.70x
PEG ratio (5yr expected):
-0.08x
EV / Free cash flow:
-0.34x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $506.1K | -- | -- | -- | -- | |
| Gross Profit | $141.7K | -- | -- | -- | -- | |
| Operating Income | -$48.9M | -$56M | -$61.8M | -$13.9M | -$15.3M | |
| EBITDA | -$48.5M | -$55.7M | -$61.4M | -$13.8M | -$15.2M | |
| Diluted EPS | -$1.84 | -$1.87 | -$1.97 | -$0.43 | -$0.49 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $153.3M | $120M | $100.6M | $55.3M | |
| Total Assets | -- | $164M | $133.7M | $113.9M | $68.6M | |
| Current Liabilities | -- | $5.3M | $7.3M | $5.6M | $6.9M | |
| Total Liabilities | -- | $5.7M | $11.8M | $9.9M | $10.8M | |
| Total Equity | -- | $158.3M | $121.9M | $104M | $57.7M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$41.6M | -$48.9M | -$52.3M | -$12M | -$13.5M | |
| Cash From Investing | $10.9M | $12.3M | $24.1M | -$24M | -$5.4M | |
| Cash From Financing | $211.2K | $28.2M | $5.4M | $21.5K | $4.4M | |
| Free Cash Flow | -$42.3M | -$49.2M | -$52.5M | -$12.1M | -$13.5M | |
IMRX
Sector
Market Cap
$68.3M
$45.6M
Price % of 52-Week High
27.78%
45.55%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-68.57%
-31.35%
Beta (5-Year)
--
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$1.84
200-day SMA
Buy
Level
$1.82
Bollinger Bands (100)
Buy
Level
1.34 - 2.4
Chaikin Money Flow
Sell
Level
-184.2M
20-day SMA
Buy
Level
$2.02
Relative Strength Index (RSI14)
Buy
Level
57.61
ADX Line
Buy
Level
10.44
Williams %R
Sell
Level
-17.0732
50-day SMA
Buy
Level
$2.01
MACD (12, 26)
Sell
Level
-0.03
25-day Aroon Oscillator
Sell
Level
-24
On Balance Volume
Neutral
Level
274.2M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
Stock Forecast FAQ
In the current month, IMRX has received 3 Buy ratings 2 Hold ratings, and 0 Sell ratings. The IMRX average analyst price target in the past 3 months is --.
-
Where Will Immuneering Stock Be In 1 Year?
According to analysts, the consensus estimate is that Immuneering share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Immuneering?
Analysts are divided on their view about Immuneering share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Immuneering is a Sell and believe this share price will drop from its current level to --.
-
What Is Immuneering's Price Target?
The price target for Immuneering over the next 1-year time period is forecast to be -- according to 5 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is IMRX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Immuneering is a Buy. 3 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of IMRX?
You can purchase shares of Immuneering via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Immuneering shares.
-
What Is The Immuneering Share Price Today?
Immuneering was last trading at $2.27 per share. This represents the most recent stock quote for Immuneering. Yesterday, Immuneering closed at $2.20 per share.
-
How To Buy Immuneering Stock Online?
In order to purchase Immuneering stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
52
TSLL alert for Dec 24
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
73
PSIX alert for Dec 24
Power Solutions International [PSIX] is up 27.42% over the past day.
Sell
31
SOXL alert for Dec 24
Direxion Daily Semiconductor Bull 3X Shares [SOXL] is up 11.87% over the past day.
